---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-015722"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T19:04:49.069395+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q3 2022 net revenue $117.2M, up 45% YoY; GAAP EPS $1.44, non-GAAP EPS $0.95

## Summary
- Net product revenue $117.2M (+45% vs Q3 2021); average WAKIX patients ~4,600.
- GAAP net income $87.9M ($1.44 diluted EPS) vs loss of $9.6M in prior year; includes $74.5M tax benefit.
- Non-GAAP adjusted net income $58.1M ($0.95 diluted EPS) vs $23.4M ($0.41) in prior year.
- PWS Phase 2 POC study positive signal on EDS; high-dose pitolisant higher responder rate vs placebo.
- Cash, cash equivalents & investments $316M as of Sep 30, 2022.

## SEC filing metadata
- accession: 0001558370-22-015722
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837022015722/0001558370-22-015722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837022015722/hrmy-20221101x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-015722
- JSON: https://secwatch.observer/filing/0001558370-22-015722.json
- Plain text: https://secwatch.observer/filing/0001558370-22-015722.txt

## Key facts
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported the quarter ended September 30, 2022 results: revenue $117.2 million, net income $87.9 million, EPS $1.44 per diluted share.
  - Period: the quarter ended September 30, 2022
  - Revenue: $117.2 million
  - Net income: $87.9 million
  - EPS: $1.44 per diluted share
  - Result: reported results
  source text: reference. --- EX-99.1 (EX-99.1) --- ‌ Exhibit 99.1 ​ HARMONY BIOSCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATES WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021 ​ Average Number of Patients on WAKIX Increased to ~4,600 ​ Prader-Willi Syndrome (PWS) Phase 2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837022015722/0001558370-22-015722-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.